Medically Reviewed on 8/26/2022

Generic Name: oteseconazole

Brand Name: Vivjoa 

Drug Class: Antifungals, systemic

What is oteseconazole, and what is it used for?

Oteseconazole is a systemic antifungal medication used to treat recurrent vulvovaginal candidiasis in women without reproductive potential.

Candidiasis is a type of yeast infection caused by Candida species of fungi. Oteseconazole may be used as monotherapy or in combination with fluconazole, another systemic antifungal medication.

Oteseconazole is a synthetic azole metalloenzyme inhibitor that works by inhibiting the activity of a fungal enzyme essential for fungal survival and growth. Oteseconazole selectively inhibits fungal sterol 14-alpha demethylase (CYP51), an enzyme essential for the formation and integrity of the fungal cell membrane. The inhibition of CYP51 results in the accumulation of 14-alpha methylated sterols which are toxic to fungi.

Oteseconazole is active against the following Candida species of fungi associated with recurrent vulvovaginal candidiasis:

  • Candida albicans
  • Candida glabrata
  • Candida krusei
  • Candida parapsilosis
  • Candida tropicalis
  • Candida lusitaniae
  • Candida dubliniensis


  • Do not use in patients with known hypersensitivity to oteseconazole or any of its components.
  • Do not use in women of reproductive potential or women who are pregnant or breastfeeding.

What are the side effects of oteseconazole?

Common side effects of oteseconazole include:

Call your doctor immediately if you experience any of the following symptoms or serious side effects while using this drug:

This is not a complete list of all side effects or adverse reactions that may occur from the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may also report side effects or health problems to the FDA at 1-800-FDA-1088.


Pelvic Pain: What's Causing Your Pelvic Pain? See Slideshow

What are the dosages of oteseconazole?


  • 150 mg
  • NOTE: Fluconazole is not supplied in carton


Vulvovaginal Candidiasis

Indicated to reduce incidence of recurrent vulvovaginal candidiasis (RVVC) in females with history of RVVC who are NOT of reproductive potential

Oteseconazole-only regimen

  • Day 1: 600 mg PO x 1 dose, THEN
  • Day 2: 450 mg PO x 1 dose, THEN
  • Beginning on Day 14: 150 mg PO qWeek for 11 weeks (Weeks 2 through 12)

Fluconazole and oteseconazole regimen

  • Days 1, 4, and 7: Fluconazole 150 mg PO x 1 dose, THEN
  • Days 14 through 20: Oteseconazole 150 mg PO qDay x 7 Days, THEN
  • Beginning on Day 28: Oteseconazole 150 mg PO qWeek for 11 weeks (Weeks 4 through 14)

Dosage Modifications

Renal impairment

  • Mild or moderate (eGFR 30-89 mL/minute): No dosage adjustment necessary
  • Severe and end-stage renal disease with or without dialysis (eGFR <29 mL/min) Not recommended

Hepatic impairment

  • Mild (Child-Pugh A): No dosage adjustment necessary
  • Moderate or severe (Child-Pugh B or C): Not recommended

Dosing Considerations


  • May institute antifungal therapy before results of fungal cultures are known
  • Once results are available, adjust antifungal therapy accordingly


  • Administer with food
  • Swallow capsule whole; do NOT chew, crush, dissolve, or open


  • Premenarchal females: Safety and effectiveness not established


  • There is insufficient information about overdose of oteseconazole. Overdose may increase the risk for severe adverse effects.
  • Oteseconazole overdose may be treated with symptomatic and supportive care.

What drugs interact with oteseconazole?

Inform your doctor of all medications you are currently taking, who can advise you on any possible drug interactions. Never begin taking, suddenly discontinue, or change the dosage of any medication without your doctor’s recommendation.

  • Oteseconazole has no severe interactions with other drugs.
  • Oteseconazole has serious interactions with the following drugs:
    • pitavastatin
    • rimegepant
  • Oteseconazole has moderate interactions with at least 37 other drugs.
  • Oteseconazole has no minor interactions with other drugs.

The drug interactions listed above are not all of the possible interactions or adverse effects. For more information on drug interactions, visit the RxList Drug Interaction Checker.

It is important to always tell your doctor, pharmacist, or health care provider of all prescription and over-the-counter medications you use, as well as the dosage for each, and keep a list of the information. Check with your doctor or health care provider if you have any questions about the medication.

Pregnancy and breastfeeding

  • Do not use oteseconazole in women who are pregnant or have reproductive potential. Animal studies show evidence of embryo-fetal toxicity from maternal use of oteseconazole.
  • Do not use oteseconazole in nursing mothers. There is insufficient information to establish safety of oteseconazole use in nursing mothers, its effects on milk production and on breastfed infants.

What else should I know about oteseconazole?

  • Take oteseconazole exactly as prescribed.
  • Store oteseconazole carefully out of reach of children.
  • In case of accidental overdose, seek medical help immediately or contact Poison Control.



Oteseconazole is a systemic antifungal medication used to treat recurrent vulvovaginal candidiasis in women without reproductive potential. Common side effects of oteseconazole include headache, sinus headache, migraine, nausea, indigestion (dyspepsia), hot flush, painful urination (dysuria), increased creatine phosphokinase (CPK) in blood, allergic dermatitis, abnormally heavy menstrual bleeding (menorrhagia), and others. Do not use in women of reproductive potential or women who are pregnant or breastfeeding.

Treatment & Diagnosis

Medications & Supplements

Prevention & Wellness

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 8/26/2022